Biogen
Search results
As the leader in RNA-targeted therapeutics for more than three decades, Ionis has focused every moment on advancing drug discovery, development, and providing hope for patients.
Ionis is building an extraordinary team and culture that is driven to deliver transformational medicines that pioneer new markets or fundamentally change the standard of care.
Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing.
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.
With approved first-in-class medicines and up to a dozen more in mid- or late-stage development, our therapeutic breakthroughs are poised to transform lives.
May 23, 2024 · Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed. Jun 18, 2024. Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema. Jun 17, 2024.
Dec 22, 2023 · The U.S. Food and Drug Administration (FDA) on Thursday approved Ionis Pharmaceuticals (IONS.O) and partner AstraZeneca's (AZN.L) drug to treat nerve damage caused by a life-shortening rare...
Ionis Pharmaceuticals, Inc. | 64,741 followers on LinkedIn. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases.
Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...
Jan 8, 2024 · In 2023, Ionis made significant progress in advancing a steady cadence of medicines for people with serious diseases, including the U.S. approval of WAINUA™ (eplontersen) for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN) and the accelerated approval of QALSODY ® (tofersen) for SOD-1 amyotrophic later...
